2-chloro-5-methylthieno[2,3-d]pyrimidin-4-amine | 87478-78-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: 2-chloro-5-methylthieno[2,3-d]pyrimidin-4-amine
• CAS: 87478-78-2
• 化学式: C₇H₆ClN₃S
• 分子量: 199.664
• InChiKey: QAZQIDWTHOPXIL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  80
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (7R)-7-甲基-1-[5-甲基-2-(2H-1,2,3-三唑-2-基)苯甲酰基]-1,4-二氮杂环庚烷 、 2-chloro-5-methylthieno[2,3-d]pyrimidin-4-amine 以 N,N-二甲基甲酰胺 为溶剂， 生成 5-methyl-2-{4-[2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl}thieno[2,3-d]pyrimidin-4-amine
  参考文献：
  名称：

  Discovery of dual orexin receptor antagonists with rat sleep efficacy enabled by expansion of the acetonitrile-assisted/diphosgene-mediated 2,4-dichloropyrimidine synthesis

  摘要：

  Recent clinical studies have demonstrated that dual orexin receptor antagonists (OX1R and OX2R antagonists or DORAs) represent a novel treatment option for insomnia patients. Previously we have disclosed several compounds in the diazepane amide DORA series with excellent potency and both preclinical and clinical sleep efficacy. Additional SAR studies in this series were enabled by the expansion of the acetonitrile-assisted, diphosgene-mediated 2,4-dichloropyrimidine synthesis to novel substrates providing an array of Western heterocycles. These heterocycles were utilized to synthesize analogs in short order with high levels of potency on orexin 1 and orexin 2 receptors as well as in vivo sleep efficacy in the rat. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.03.052
• 作为产物：
  描述：

  2,4-二氯-5-甲基噻吩并[2,3-D]嘧啶 在 氨 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 48.0h， 生成 2-chloro-5-methylthieno[2,3-d]pyrimidin-4-amine
  参考文献：
  名称：

  Substituted diazepan orexin receptor antagonists

  摘要：

  本发明涉及替代二氮杂环丙烷化合物，其为促进睡眠蛋白受体的拮抗剂，可用于治疗或预防神经和精神疾病，以及涉及促进睡眠蛋白受体的疾病。该发明还涉及包含这些化合物的药物组合物，以及利用这些化合物和组合物在预防或治疗涉及促进睡眠蛋白受体的疾病中的用途。

  公开号：

  US20080132490A1

文献信息

• Substituted diazepan orexin receptor antagonists
  申请人：Bergman Jeffrey M.

  公开号：US20080132490A1

  公开（公告）日：2008-06-05

  The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及替代二氮杂环丙烷化合物，其为促进睡眠蛋白受体的拮抗剂，可用于治疗或预防神经和精神疾病，以及涉及促进睡眠蛋白受体的疾病。该发明还涉及包含这些化合物的药物组合物，以及利用这些化合物和组合物在预防或治疗涉及促进睡眠蛋白受体的疾病中的用途。
• Thienopyrimidine derivatives, their preparation and their medical use
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0082023A2

  公开（公告）日：1983-06-22

  Compounds of formula (I): [wherein R1 represents a variety of aliphatic diamino or triami- no groups, a 6- or 7- membered heterocyclic ring containing two nitrogens, one of which is optionally substituted or a tetrahydro-1,4-thiazin-4-yl group; R2 represents an optionally mono- or di- alkyl-substituted amino group, a mono- or di-(2-hydroxyethyl)-substituted amino group or an optionally mono- or di- alkyl-substituted aminoethylamino group; and R3 and R4 each represents hydrogen or C1-C4 alkyl or together represent tri- to penta- methylene] and salts thereof may be prepared by reacting an equivalent compound, but in which the groups R1 and R2 are replaced by leaving groups, with compounds R'H (in which free amino groups are optionally protected) and R2H. Various of the compounds have one or more of the following activities: hypoglycaemic activity; the ability to inhibit aggregation of blood platelets; hypotensive activity; or diuretic activity. They can be used in the treatment or prophylaxis of thrombosis, hyperglycaemia, hypertension or oedema and may be formulated as compositions with conventional pharmaceutical carriers or diluents.

  式(I)化合物： [其中 R1 代表各种脂肪族二氨基或三氨基、含有两个硝基（其中一个被任选取代）的 6-或 7-成员杂环或四氢-1,4-噻嗪-4-基；R2 代表任选的单-或二-烷基取代的氨基、单-或二-（2-羟乙基）取代的氨基或任选的单-或二-烷基取代的氨基乙氨基；R3和R4各自代表氢或C1-C4烷基，或共同代表三亚甲基至五亚甲基]及其盐类可通过将等效化合物（但其中基团R1和R2被离去基团取代）与化合物R'H（其中游离氨基可任选被保护）和R2H反应制备。这些化合物具有以下一种或多种活性：降血糖活性；抑制血小板聚集的能力；降血压活性；或利尿活性。它们可用于治疗或预防血栓形成、高血糖、高血压或水肿，并可与常规药物载体或稀释剂配制成组合物。
• Substituted diazepan compounds as orexin receptor antagonists
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2392572A1

  公开（公告）日：2011-12-07

  The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及取代的二氮杂环庚烷化合物，它们是奥曲肽受体的拮抗剂，可用于治疗或预防涉及奥曲肽受体的神经和精神紊乱及疾病。本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在预防或治疗涉及奥曲肽受体的此类疾病中的用途。
• SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS
  申请人：Bergman Jeffrey M.

  公开号：US20110195957A1

  公开（公告）日：2011-08-11

  The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
• US7951797B2
  申请人：——

  公开号：US7951797B2

  公开（公告）日：2011-05-31